ArticleScientific reports2026
Metabolic and cardiovascular profiles in diabetes type 2: a comparative analysis of zinc homeostasis and blood pressure-a single center case-control study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Funding
Abstract
Zinc plays an important role in glucose metabolism and lipid regulation, and its imbalance has been implicated in the development of type 2 diabetes, metabolic syndrome, and dyslipidemia. A case-control study was conducted on 100 patients with type 2 diabetes and 95 controls. Serum zinc levels, metabolic panel and Blood pressure, were measured. Demographic and treatment-related factors were assessed to evaluate their potential influence on trace element status. Moreover, dietary zinc consumption was estimated. Diabetic patients had significantly lower serum zinc levels compared to non-diabetic participants despite comparable intake. In addition, each unit (mcg/dL) increase in serum zinc was associated with 10% lower odds of diabetes prevalence (p = 0.003). Total TC, TG, and LDL were all significantly increased in patients with diabetes (p < 0.001), each 1 mg/dL increase in LDL-cholesterol increased the odds of zinc deficiency by 4% (p = 0.03). Individuals with diabetes had significantly lower diastolic blood pressure as compared to healthy participants (p = 0.01). People with diabetes display different blood pressure and lipid patterns, as well as lower serum zinc concentrations, despite having dietary zinc intake comparable to those without diabetes. Higher serum zinc levels are associated with reduced odds of having diabetes. However, because these findings are based on cross-sectional data, further longitudinal and intervention studies are needed to determine the most effective zinc formulations and dosing regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.